Our Projects

RLT-Connect is an online platform designed to facilitate collaboration between healthcare professionals seeking targeted radionuclide therapy (TRT) for their patients who cannot afford it and radioisotope suppliers willing to donate doses, making this life-changing treatment accessible to those in need.

With over 1,000 therapy centers worldwide, this interactive global map is designed to help you find where targeted radionuclide therapy (TRT) is available. Explore the map to locate specialized centers providing these advanced treatments.

Radiotheranostics is changing cancer care, shifting treatment from a one-size-fits-all model to a personalised approach. Yet it remains widely misunderstood. To bridge that gap, the Oncidium foundation created Mister Bind, an educational hero who guides you through this innovative technique with comic books and videos, available in multiple languages.

Every March 31, we celebrate World Radiotheranostics Day, honoring an innovation that has been transforming cancer care since 1941. Under the theme #SeeitTreatit, this global awareness campaign brings together patients, healthcare professionals, and supporters to raise visibility, share resources, and advocate for greater access. Be part of it.

Patients discovering targeted radionuclide therapy face a double challenge: understanding the science and finding someone who has actually been through it. RLT Channel bridges that gap. Each episode pairs interviews with oncologists and nuclear medicine specialists, who explain how the therapy works and how to access it, with patient testimonials that bring the experience to life, offering something a brochure cannot: reassurance, perspective, and the certainty of not navigating this alone.

Bringing experts, policymakers, and healthcare leaders together to accelerate access to targeted radionuclide therapy (TRT) where it is most needed. Organised by the Oncidium foundation, the Regional Radiotheranostics Summits create space for shared learning across continents and build local momentum to expand access to this life-changing treatment.

Access to cancer care should not require a legal fight. In Argentina, insurance providers often deny coverage, and people living with cancer must pursue judicial appeals to obtain radioligand therapy. For most who would be eligible, this puts treatment out of reach. The Oncidium foundation has partnered with Fundación ACIAPO, a local patient organization, to lead advocacy efforts. Together, we work to raise public awareness, amplify patient voices, and engage national health authorities, expanding access to RLT for those who need it.

Across Europe, access to radioligand therapy still depends too much on where a person lives. The Oncidium foundation works with policymakers and partners to share patient realities and advocate for fairer access to innovative cancer care.

Thera4Care specializes in advanced theranostic solutions, combining expert research with novel technologies to revolutionise healthcare.

Our approach enhances precision in both diagnostics and treatments for complex diseases like cancer, utilizing innovative isotopes and imaging techniques to improve patient outcomes.

Accelerate.EU is a project pioneering the development of novel radiotheranostic pairs featuring the alpha-emitting isotope astatine-211 (211At) to target aggressive cancers like pancreatic, breast, and brain cancer.